前列地尔对乙肝肝硬化患者血清炎性因子及肝功能的影响

发布时间：2018-03-23 06:36

本文选题：乙肝肝硬化　切入点：前列地尔　出处：《医学研究生学报》2017年06期 　论文类型：期刊论文

【摘要】：目的前列地尔可以提高乙肝肝硬化患者的临床疗效,但其对血清炎性因子影响的文献较少。文中旨在探讨前列地尔对乙肝肝硬化患者血清炎性因子及肝功能的影响,分析前列地尔治疗乙肝肝硬化的可能机制。方法选择2014年8月至2015年7月西南医科大学附属医院消化内科收治的162例乙肝肝硬化患者为研究对象。采用随机数字表法随机分为观察组(联合应用前列地尔治疗)和对照组(抗病毒、保肝及支持治疗),每组81例。观察2组治疗前后血清炎性因子白细胞介素-6(IL-6)、高敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)含量,检测谷氨酸-丙酮酸转氨酶(ALT)、总胆红素(TBil)、凝血酶原活动度(PTA)等肝功能指标的变化。结果观察组总有效率明显高于对照组(82.72%vs 62.96%,P0.05)。观察组治疗4周后血清炎性因子IL-6[(97.15±19.73)pg/mL]、hs-CRP[(50.23±6.69)ng/L]、TNF-α[(85.45±13.61)pg/mL];肝功能指标ALT[(96.13±23.62)μmol/L]、TBil[(271.55±25.12)μmol/L]、PTA[(68.36±8.11)%]含量较治疗前[(275.62±43.39)pg/mL、(425.54±55.58)ng/L、(321.74±80.73)pg/mL;(139.54±37.36)μmol/L、(395.39±41.13)μmol/L、(38.50±4.19)%]均明显改善(P0.05)。观察组上述指标含量治疗前后变化幅度明显优于对照组(P0.05)。结论前列地尔有助于缓解乙肝肝硬化患者炎症状态,更好地改善肝功能,提高临床疗效。
[Abstract]:Objective to investigate the effect of alprostadil on serum inflammatory factors and liver function in patients with hepatitis B cirrhosis. To analyze the possible mechanism of alprostadil in the treatment of hepatitis B cirrhosis. Methods 162 patients with hepatitis B cirrhosis treated in the Department of Digestive Medicine, Southwest Medical University affiliated Hospital from August 2014 to July 2015 were selected as subjects. Random numbers were used. The table method was randomly divided into observation group (combined with alprostadil therapy) and control group (antiviral therapy). 81 cases in each group were treated with liver protection and supportive therapy. The levels of serum inflammatory cytokines, interleukin-6, Gao Min C-reactive protein hs-CRPU, tumor necrosis factor- 伪 (TNF- 伪) before and after treatment were observed. The changes of liver function such as glutamic acid-pyruvate transaminase (alt), total bilirubin (Tbilirubin) and prothrombin activity (PT) were detected. Results the total effective rate in the observation group was significantly higher than that in the control group (82.72 vs 62.96) P0.05.The serum inflammatory factor IL-6 [97.15 卤19.73)pg/mL] hs-CRP [50.23 卤6.69)ng/L] [50.23 卤6.69)ng/L] [85.45 卤13.61)pg/mL] was detected in the observation group after 4 weeks of treatment. The content of ALT [68.36 卤8.11%] was significantly better than that before and after treatment [275.62 卤43.39 卤425.58 ng / L, 321.74 卤80.73 mg / L, 139.54 卤37.36) 渭 mol / L, 395.39 卤41.13 渭 mol / L / L ~ (38.50 卤4.19) 渭 mol / L 路L ~ (-1) and 38.50 卤4.19 渭 mol / L ~ (-1), respectively. Conclusion the changes of the above indexes in the observation group are obviously better than those in the control group before and after treatment. Better improve liver function, improve clinical efficacy.
【作者单位】：西南医科大学附属医院消化内科;
【基金】：国家自然基金(81672458)
【分类号】：R512.62;R575.2

【相似文献】